Notice Regarding National Shortage of Adderall IR

November 9, 2022

U.S. Shortage of Adderall Immediate Release (IR) (amphetamine mixed salts)

On October 12, 2022, the Food and Drug Administration (FDA) announced a shortage of the IR formulation of amphetamine mixed salts, commonly referred to by the brand name Adderall or Adderall IR.  Amphetamine mixed salts, including Adderall, are FDA-approved for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. 

The shortage is due to the major manufacturer of amphetamine mixed salts, Teva, experiencing intermittent manufacturing delays.  Other manufacturers continue to produce amphetamine mixed salts, but there is insufficient supply to meet U.S. market demand through those producers.

Effective 01 December 2022 all NCR Market pharmacies will restrict the filling of amphetamine mixed salts IR tablet prescriptions to a maximum 30-day supply, except for deployment-related requests.

Until supply is restored, alternative therapies include the extended-release version of amphetamine mixed salts or other stimulant medications as deemed appropriate by your health care provider. Please discuss your treatment options with your provider do determine your best care plan during this shortage period.
          
The NCR Market will continue to closely monitor our supply, the status of the national shortage, and provide updates as they become available.  Thank you for your patience and allowing us to meet your health care needs.

If you have any questions about this notice, please contact your local military pharmacy in the NCR Market.